Janssen Submits Regulatory Application to European Medicines Agency for Rilpivirine Long Acting, to Be Used in Combination with Cabotegravir Long Acting, as the First Monthly Injectable Treatment for HIV
The marketing application is based on Phase 3 ATLAS and FLAIR pivotal trials in which the once-monthly injectable treatment regimen…